OHRP has experienced an unprecedented exodus of ethics expertise, raising concerns about its ability to effectively protect ...
Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental ...
Assessing the health secretary's biggest challenges, and a look at new rules that inject politics into the NIH.
The listening session, held on the FDA’s White Oak Campus, featured 17 speakers representing patient groups, drug companies, ...
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with ...
A senior NIH scientist and his research fellow were charged with smuggling vials of deactivated mpox virus into the country ...
You have to understand a person's belief if you want to address it,” Deva Sharma says on the “First Opinion Podcast” about ...
For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might ...
Biomedical researchers and policy experts decried the change when it was proposed this spring. STAT’s Anil Oza has the latest ...
A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using ...
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results